CART
Your cart is empty
AN INDEPENDENT STUDY ON HEMP BEVERAGES BY MOREBETTER
Woodstock has been studied in two independent trials with MoreBetter, tracking hundreds of participants over 22 days each using validated clinical instruments — the WHO-5 Well-Being Index and the DASS-21. Participants who drank Woodstock were significantly less likely to drink alcohol, reported measurable reductions in anxiety, stress, and depression, and slept better than during their baseline period.
Each Woodstock beverage was studied independently and produced its own distinct results. Follow the links below to see the full data for each product.
2.5 MG
THC
44% drop in alcohol consumption probability. 77% of participants drank less alcohol overall. 65% less anxiety. 30 more minutes of sleep per night.
2.5 MG
THC
47.3% drop in alcohol probability. The only hemp beverage in the study to show dual substitution — displacing both alcohol and cannabis on product-use days. Results consistent across all ages, genders, and dose levels.
5 MG
THC
31.85% improvement in WHO-5 Well-Being scores — more than triple the clinically meaningful threshold. 90.9% of participants said it's safer than alcohol for their health.
5 MG
THC
62.9% drop in anxiety — the strongest mood outcome in the portfolio. The only product to show statistically significant pain reduction. 27.6% boost in next-day productivity.
MoreBetter is a real-world evidence research platform that partners with brands and research institutions to track how consumer products affect daily health outcomes.
Their methodology captures what clinical trials can't: how people actually use products in their real lives, at their own pace, without being told what to do.
Each study followed the same design: 7 days of baseline reporting, then 14 days using a Woodstock beverage at whatever frequency felt natural. Participants reported daily on alcohol use, cannabis use, mood, sleep, stress, anxiety, and productivity — measured against the WHO-5 and DASS-21.
MoreBetter’s second Woodstock study — part of a broader Infused Beverage Study spanning nearly 5,000 participants across two cohorts — focused on three additional flavors: Citrus Spritz, Yuzu Ginger, and Raspberry Lychee.
Each product was studied independently and produced its own distinct results.
Findings from this study were presented publicly at a webinar co-hosted by MoreBetter and the Network of Applied Pharmacognosy (NAP) a 501(c)(3) nonprofit led by Dr. Miyabe Shields, PhD and Dr. Riley Kirk, PhD — titled “Cannabis vs. Alcohol: Real-World Data from MoreBetter’s Infused Beverage Study,” in June 2026.
Across both MoreBetter studies, Woodstock participants reported a 44–47% reduction in alcohol consumption probability on product-use days, up to 77% reported drinking less alcohol overall, anxiety fell 27–63% depending on the product, sleep improved by 19–30 minutes per night, and next-day productivity increased by up to 27.6%.
| METRIC | RESULT |
|---|---|
| Alcohol consumption probability (product-use days) | ↓ 44–47% depending on product |
| Participants reporting less alcohol overall | Up to 77% |
| Anxiety reduction (DASS-21) | ↓ 27–63% depending on product |
| Sleep improvement | +19–30 min/night |
| Next-day productivity boost | Up to +27.6% |
| Study duration | 22 days per product |
| Total participants | ~5,000 across two cohorts |
| Study platform | MoreBetter / Network of Applied Pharmacognosy |
Real-world evidence research tracks how products affect daily outcomes among people using them naturally — not in a controlled lab setting. It captures behavioral and self-reported data over time, making it more representative of how products actually perform in everyday life than single-session clinical trials.
No. Both studies were non-interventional. Participants used the products at whatever frequency felt natural during the 14-day product-use phase. The results reflect organic behavior, not prescribed dosing.
Both studies used validated clinical instruments: the WHO-5 Well-Being Index (overall wellbeing) and the DASS-21 (depression, anxiety, and stress). Both are widely used in academic and clinical research worldwide.
No. All results use participant-reported attribution and reflect behavioral and self-reported outcomes. This is not clinical treatment data. Individual results may vary.
Findings were presented publicly at the NAP × MoreBetter webinar "Cannabis vs. Alcohol: Real-World Data from MoreBetter's Infused Beverage Study" in June 2026.
Data cited on this page comes from MoreBetter’s Dark Berries Quality of Life & Alcohol Consumption/Desire Data Report (June 2025) and MoreBetter’s Infused Beverage Study, Cohorts 1 and 2, conducted in partnership with the Network of Applied Pharmacognosy. All claims use participant-reported attribution. Results reflect behavioral and self-reported outcomes, not clinical treatment.
Last Updated: Data as of June 2026
Dr. Miyabe Shields, PhD and Dr. Riley Kirk, PhD are the co-founders of the Network of Applied Pharmacognosy, a 501(c)(3) nonprofit research organization. Both are academically trained pharmaceutical scientists with backgrounds in drug discovery, the endocannabinoid system, and natural products chemistry. NAP partnered with MoreBetter to present findings from the second study at a public webinar in June 2026, contextualizing the beverage data within the broader science of cannabis pharmacology and alcohol substitution.
